Ladislav Bumba Selected Research

Adenylate Cyclase Toxin

1/2021	Almost half of the RTX domain is dispensable for complement receptor 3 binding and cell-invasive activity of the Bordetella adenylate cyclase toxin.
11/2020	Acellular Pertussis Vaccine Inhibits Bordetella pertussis Clearance from the Nasal Mucosa of Mice.
1/2018	Bordetella Pertussis Adenylate Cyclase Toxin Does Not Possess a Phospholipase A Activity; Serine 606 and Aspartate 1079 Residues Are Not Involved in Target Cell Delivery of the Adenylyl Cyclase Enzyme Domain.
1/2016	Negatively charged residues of the segment linking the enzyme and cytolysin moieties restrict the membrane-permeabilizing capacity of adenylate cyclase toxin.
12/2015	Bordetella adenylate cyclase toxin is a unique ligand of the integrin complement receptor 3.
11/2015	Bordetella adenylate cyclase toxin: a unique combination of a pore-forming moiety with a cell-invading adenylate cyclase enzyme.
1/2014	Bordetella adenylate cyclase toxin differentially modulates toll-like receptor-stimulated activation, migration and T cell stimulatory capacity of dendritic cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ladislav Bumba Research Topics

Disease

9	Whooping Cough (Pertussis) 01/2022 - 01/2012
5	Infections 01/2022 - 12/2009
4	Neoplasms (Cancer) 10/2022 - 01/2018
1	Adenocarcinoma 08/2021
1	Melanoma (Melanoma, Malignant) 10/2020
1	Prostatic Neoplasms (Prostate Cancer) 10/2020
1	Neoplasm Metastasis (Metastasis) 10/2020
1	Atrophic Rhinitis (Ozena) 01/2020
1	Respiratory Tract Infections (Respiratory Tract Infection) 08/2018
1	Meningococcal Infections 10/2015
1	Pain (Aches) 05/2012
1	Wasting Syndrome (Wasting Disease) 12/2009

Drug/Important Bio-Agent (IBA)

7	Adenylate Cyclase ToxinIBA 01/2021 - 01/2014
4	Galectin 3 (LGALS3)IBA 10/2022 - 01/2018
3	Complement Receptors (Complement Receptor)IBA 01/2021 - 12/2015
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 12/2009
3	Hemolysin Proteins (Hemolysins)IBA 01/2018 - 11/2015
3	Virulence Factors (Pathogenicity Factors)IBA 12/2015 - 01/2014
2	AntibodiesIBA 01/2022 - 12/2009
2	ToxoidsIBA 01/2022 - 11/2020
2	Adenylyl Cyclases (Adenylyl Cyclase)IBA 01/2022 - 11/2020
2	AntigensIBA 11/2020 - 12/2009
2	Biological ProductsIBA 10/2020 - 05/2012
2	IntegrinsIBA 01/2017 - 12/2015
1	Immunoglobulin G (IgG)IBA 01/2022
1	Glycoproteins (Glycoprotein)IBA 08/2021
1	Neutralizing AntibodiesIBA 11/2020
1	VaccinesIBA 11/2020
1	salicylhydroxamic acid (SHAM)IBA 11/2020
1	hydroxypropyl methacrylateIBA 10/2020
1	N- acetylgalactosaminyl- 1- 4- N- acetylglucosamineIBA 10/2020
1	2,6-dinitrotoluene (DNT)IBA 01/2020
1	Hemagglutinins (Hemagglutinin)IBA 08/2018
1	LectinsIBA 01/2018
1	Ion Channels (Ion Channel)IBA 05/2012
1	CationsIBA 05/2012
1	CalciumIBA 01/2012
1	Capsid Proteins (Capsid Protein)IBA 12/2009

Therapy/Procedure

4	Therapeutics 10/2022 - 01/2018
1	Surgical Instruments (Clip) 01/2020